文献速递肾血管病与高血压

动脉粥样硬化性肾血管疾病:欧洲肾脏协会欧洲肾脏最佳实践委员会与欧洲高血压学会高血压与肾脏工作组的临床实践文件

Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH).
PubMed 文献 · Nephrol Dial Transplant · 2023-01-01

本临床实践文件由欧洲肾脏协会欧洲肾脏最佳实践委员会与欧洲高血压学会高血压与肾脏工作组的专家制定,总结动脉粥样硬化性肾血管疾病的流行病学、病理生理与诊断评估,并经系统文献回顾提出治疗关键证据,以支持临床决策与日常管理。

要点

  • 动脉粥样硬化性肾血管疾病是肾动脉狭窄最常见类型,未来心血管和肾脏事件及全因死亡风险高。
  • 随机对照试验未证实经皮腔内肾动脉血管成形术联合或不联合支架置入在标准药物治疗基础上较单纯药物治疗更优。
  • 观察性研究显示,经皮腔内肾动脉血管成形术与高危表型患者的未来心肾获益相关。

核心结论

  • 随机对照试验未证明经皮腔内肾动脉血管成形术联合或不联合支架置入加标准药物治疗在降低血压或预防不良肾脏和心血管结局方面优于单纯药物治疗。
  • 观察性研究显示经皮腔内肾动脉血管成形术与高危动脉粥样硬化性肾血管疾病表型患者的未来心肾获益相关。

研究设计与样本

  • 本文件由欧洲肾脏协会欧洲肾脏最佳实践委员会与欧洲高血压学会高血压与肾脏工作组的专家制定。
  • 文件总结动脉粥样硬化性肾血管疾病的流行病学、病理生理与诊断评估,并经系统文献回顾提出治疗关键证据。

主要发现

  • 动脉粥样硬化性肾血管疾病是肾动脉狭窄最常见类型,是常见健康问题,临床呈现涉及多个医学专科。
  • 该病未来心血管和肾脏事件及全因死亡风险高。
  • 关于动脉粥样硬化性肾血管疾病管理的现有证据存在矛盾。
  • 随机对照试验存在若干局限并受到重要批评。

关键数值与推荐

  • 高危动脉粥样硬化性肾血管疾病表型包括急性肺水肿、难治性高血压或肾功能快速丧失。

临床怎么用

  • 本文件旨在支持临床医生对动脉粥样硬化性肾血管疾病患者的决策与日常管理。

局限性

  • 关于动脉粥样硬化性肾血管疾病管理的现有证据存在矛盾。
  • 随机对照试验存在若干局限并受到重要批评。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atherosclerotic renovascular disease (ARVD) is the most common type of renal artery stenosis. It represents a common health problem with clinical presentations relevant to many medical specialties and carries a high risk for future cardiovascular and renal events, as well as overall mortality. The available evidence regarding the management of ARVD is conflicting. Randomized controlled trials failed to demonstrate superiority of percutaneous transluminal renal artery angioplasty (PTRA) with or without stenting in addition to standard medical therapy compared with medical therapy alone in lowering blood pressure levels or preventing adverse renal and cardiovascular outcomes in patients with ARVD, but they carried several limitations and met important criticism. Observational studies showed that PTRA is associated with future cardiorenal benefits in patients presenting with high-risk ARVD phenotypes (i.e. flash pulmonary oedema, resistant hypertension or rapid loss of kidney function). This clinical practice document, prepared by experts from the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and from the Working Group on Hypertension and the Kidney of the European Society of Hypertension (ESH), summarizes current knowledge in epidemiology, pathophysiology and diagnostic assessment of ARVD and presents, following a systematic literature review, key evidence relevant to treatment, with an aim to support clinicians in decision making and everyday management of patients with this condition.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Sarafidis PA, Theodorakopoulou M, Ortiz A, et al. Atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2023. PMID: 37202218. doi:10.1093/ndt/gfad095

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。